Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. Am J Coll Cardiol. 2018;72:e91-e220.
Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation. 2015;132:1613-1619.
Marrouche NF, Brachmann J, Andresen D, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-427.
McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
Olgin JE, Pletcher M, Vittinghoff E, et al. Efficacy of a wearable cardioverter-defibrillator after myocardial infarction: results of the Vest Prevention of Early Sudden Death Trial (VEST). Presented at: American College of Cardiology Annual Scientific Session (ACC 2018); March 10, 2018; Orlando, FL. Abstract 401-10.
Olgin JE, Pletcher MJ, Vittinghoff E, et al; VEST Investigators. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379:1205-1215.
Packer DL, Mark DB, Robb RA, et al; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261-1274.
Piccini JP Sr, Allen LA, Kudenchuk PJ, et al; on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. Circulation. 2016;133:1715-1727.
Solomon SD, Zelenkofske S, McMurray JJ, et al; Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-2588.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Manesh R. Patel, MD

Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Disclosures

Disclosure: Manesh R. Patel, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Procyrion Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Procyrion Inc.

Faculty

Ilan Goldenberg, MD

Professor of Cardiology
Director
Clinical Cardiovascular Research Center
University of Rochester Medical Center
Rochester, New York

Disclosures

Disclosure: Ilan Goldenberg, MD, has disclosed no relevant financial relationships.

Editor

George Boutsalis, PhD

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

Chris Washburn, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Chris Washburn, PhD, has disclosed no relevant financial relationships.

Asha P. Gupta, PharmD, RPh

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Asha P. Gupta, PharmD, RPh, has disclosed no relevant financial relationships.

CME/CE Reviewers

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: Abbott Laboratories

CME / ABIM MOC / CE

The Power of As-Treated Analyses: What Have We Learned From VEST?

Authors: Manesh R. Patel, MD; Ilan Goldenberg, MD
CME / ABIM MOC / CE Released: 9/10/2019; Reviewed and Renewed: 11/5/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/5/2021

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, emergency medicine physicians, critical care specialists, and nurses.

The goal of this activity is to improve knowledge regarding clinical trial methodology and data supporting the use of wearable cardioverter-defibrillator (WCD), and the use of effective healthcare provider (HCP)-patient communication strategies to improve prevention of sudden cardiac death (SCD).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial methodology, including the differences between "as treated" vs "intent-to-treat" analyses
- Clinical data supporting the use of WCD, including randomized clinical trials and real-world evidence
Have greater competence related to
- Use of effective HCP-patient communication strategies to improve SCD prevention

Disclosures

Moderator

Manesh R. Patel, MD

Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Disclosures

Disclosure: Manesh R. Patel, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Procyrion Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Procyrion Inc.

Faculty

Ilan Goldenberg, MD

Professor of Cardiology
Director
Clinical Cardiovascular Research Center
University of Rochester Medical Center
Rochester, New York

Disclosures

Disclosure: Ilan Goldenberg, MD, has disclosed no relevant financial relationships.

Editor

George Boutsalis, PhD

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

Chris Washburn, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Chris Washburn, PhD, has disclosed no relevant financial relationships.

Asha P. Gupta, PharmD, RPh

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Asha P. Gupta, PharmD, RPh, has disclosed no relevant financial relationships.

CME/CE Reviewers

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: Abbott Laboratories

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

The Power of As-Treated Analyses: What Have We Learned From VEST?

Authors: Manesh R. Patel, MD; Ilan Goldenberg, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 9/10/2019; Reviewed and Renewed: 11/5/2020

Valid for credit through: 11/5/2021

processing....

Before you begin this activity, please assess your clinical knowledge by completing this brief survey.

Page 1 of 2

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Manesh R. Patel, MD

Faculty

Ilan Goldenberg, MD

Editor

George Boutsalis, PhD

Chris Washburn, PhD

Asha P. Gupta, PharmD, RPh

CME/CE Reviewers

Esther Nyarko, PharmD

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

CME / ABIM MOC / CE

The Power of As-Treated Analyses: What Have We Learned From VEST?

Target Audience and Goal Statement

Disclosures

Moderator

Manesh R. Patel, MD

Faculty

Ilan Goldenberg, MD

Editor

George Boutsalis, PhD

Chris Washburn, PhD

Asha P. Gupta, PharmD, RPh

CME/CE Reviewers

Esther Nyarko, PharmD

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

The Power of As-Treated Analyses: What Have We Learned From VEST?